Renaissance Group LLC Grows Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

Renaissance Group LLC boosted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 27.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 56,357 shares of the specialty pharmaceutical company’s stock after purchasing an additional 12,297 shares during the period. Renaissance Group LLC owned about 0.09% of Jazz Pharmaceuticals worth $5,981,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of JAZZ. LSV Asset Management grew its holdings in Jazz Pharmaceuticals by 3.6% during the second quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock worth $271,003,000 after acquiring an additional 87,576 shares during the period. Dimensional Fund Advisors LP boosted its position in Jazz Pharmaceuticals by 14.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock worth $289,066,000 after purchasing an additional 293,360 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Jazz Pharmaceuticals by 4.7% in the 1st quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company’s stock worth $206,343,000 after purchasing an additional 74,501 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 41.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock worth $165,245,000 after purchasing an additional 391,660 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Jazz Pharmaceuticals by 1.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,171,755 shares of the specialty pharmaceutical company’s stock valued at $124,366,000 after purchasing an additional 16,757 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on JAZZ. Truist Financial raised their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Royal Bank Of Canada set a $194.00 target price on Jazz Pharmaceuticals and gave the company an “outperform” rating in a research report on Monday. Robert W. Baird increased their price target on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research report on Tuesday. Weiss Ratings restated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research note on Monday, October 27th. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $195.07.

Jazz Pharmaceuticals Stock Up 6.1%

NASDAQ JAZZ opened at $180.52 on Wednesday. The business has a fifty day moving average price of $135.92 and a 200 day moving average price of $121.19. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $182.99. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The company has a market cap of $10.97 billion, a P/E ratio of -26.82, a P/E/G ratio of 8.49 and a beta of 0.29.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.87 by $2.26. The company had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.54 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. Research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the transaction, the director directly owned 429,973 shares in the company, valued at $55,303,127.26. The trade was a 1.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders have sold 11,500 shares of company stock valued at $1,525,280. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.